There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
This study compared the risk for major bleeding (MB) and healthcare economic outcomes
of patients with non-valvular atrial fibrillation (NVAF) after initiating treatment
with apixaban vs rivaroxaban, dabigatran, or warfarin.